Posology : מינונים

4.2    Posology and method of administration

Paloxi should be used only before chemotherapy administration. This medicinal product should be administered by a healthcare professional under appropriate medical supervision.

Posology
Adults

250 micrograms palonosetron administered as a single intravenous bolus approximately 30 minutes before the start of chemotherapy. Paloxi should be injected over 30 seconds.
The efficacy of Paloxi in the prevention of nausea and vomiting induced by highly emetogenic chemotherapy may be enhanced by the addition of a corticosteroid administered prior to chemotherapy.

Elderly people

No dose adjustment is necessary for the elderly.
Paediatric population

Children and Adolescents (aged 1 month to 17 years):
20 micrograms/kg (the maximum total dose should not exceed 1500 micrograms) palonosetron administered as a single 15 minute intravenous infusion beginning approximately 30 minutes before the start of chemotherapy.
The safety and efficacy of Paloxi in children aged less than 1 month have not been established. No data are available. There are limited data on the use of Paloxi in the prevention of nausea and vomiting in children under 2 years of age.


Hepatic impairment
No dose adjustment is necessary for patients with impaired hepatic function.

Renal impairment

No dose adjustment is necessary for patients with impaired renal function.
No data are available for patients with end stage renal disease undergoing haemodialysis.
Method of administration
For intravenous use.